论文部分内容阅读
目的探讨~(125)Ⅰ放射性粒子植入治疗C期激素难治性前列腺癌的临床疗效。方法本组11例,均通过前列腺穿刺活检确诊为前列腺癌,G1eason评分6～9分,经内分泌治疗后确认进展为激素难治性前列腺癌时平均PSA为1 0.91 ng/ml,临床分期均为C期,行直肠B超引导下,经会阴穿刺植入放射性~(125)Ⅰ粒子治疗。结果全组患者手术顺利,手术时间30～70min,平均植入粒子49粒,均于术后3～6d出院。术后随访3～71个月,平均3 1个月。完全有效3例,部分有效1例,病情稳定3例,无效3例,失访1例,PSA无进展生存率70%(7/1 0)。无效患者3例中,2例PSA无进展生存期达2年以上。所有患者术后均未出现严重并发症。结论 ~(125)Ⅰ放射性粒子植入治疗C期激素难治性前列腺癌安全、有效。
Objective To investigate the clinical efficacy of ~ (125) Ⅰ radioactive seed implantation in treatment of hormone refractory prostate cancer. Methods The group of 11 patients were diagnosed as prostate cancer by prostate biopsy, G1eason score of 6 to 9, after endocrine therapy to confirm the progress of hormone refractory prostate cancer average PSA was 1 0.91 ng / ml, the clinical stage were C, under the guidance of rectum B-ultrasound, the perineal puncture radioactive 125I Ⅰ particle implantation. Results All the patients underwent surgery successfully. The operation time was 30-70 minutes, with an average of 49 particles implanted. All patients were discharged at 3 to 6 days after operation. The patients were followed up for 3 to 71 months with an average of 31 months. 3 cases were completely effective, 1 partially effective, 3 stable, 3 ineffective, 1 missed follow-up. The progression-free survival rate of PSA was 70% (7/1 0). In 3 invalid patients, 2 patients with PSA progression-free survival of more than 2 years. No serious complications occurred in all patients after operation. Conclusion 125I Ⅰ radioactive seed implantation is safe and effective in the treatment of stage C hormone refractory prostate cancer.